source
- Moderna and Merck’s mRNA success fuels focus on ‘scaling out and scaling down’After mastering mass-market mRNA production during the pandemic, the industry now needs to achieve the timely delivery of individualized vaccines to thousands of patients.BioSpace · 31m ago↗ source
- Reeling from past failures, Parkinson's pipeline enters 'era of diversification'While some drugmakers continue to walk the alpha-synuclein antibody path, others like AC Immune opt for new approaches that could bring the first-ever disease-modifying therapy for Parkinson's dise…BioSpace · 37m ago↗ source
- Novo Nordisk halts two cardiovascular trials of inflammation-targeting drug ziltivekimabNovo Nordisk announced it is halting the HERMES and ATHENA cardiovascular trials of its experimental drug ziltivekimab, which was intended to lower inflammation to improve heart health. A data mon…